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 Oct1 and its transcriptional cofactor OCA-B are required for memory CD4
+ 
T 





T cells have no endogenous expression of OCA-B. After 6 hours of in vitro 
stimulation, by plate bound CD3ε antibodies and CD28 antibodies in media, T cells begin 
expression of OCA-B. OCA-B expression increases gradually over time with continued 
stimulation. Maintenance of OCA-B expression is influenced by Oct1 activity: in the 
absence of Oct1, OCA-B levels are reduced at long time points following stimulation. 
Additionally, a novel function of OCA-B positively influencing surface expression of 
CD44, a surface receptor required for memory T cell survival, has been discovered.  
A floxed, conditional cre-driven knockout allele of OCA-B has been generated in 
C57/BL6 mice. This allele will prove to be an invaluable tool for researching further in 
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Octamer transcription factor Oct1 
 A subset of POU (Pit-1, Oct1/2, Unc-86) domain transcription factors, referred to 
as Oct proteins or octamer transcription factors, recognize the highly conserved 8 base 
pair sequence [ATGC(A/T)AAT], known as the “octamer motif” (1). The class V Oct 
protein Oct4 (Pou5f1, Oct3), a key factor in induced pluripotent stem cell development, is 
perhaps the most renowned, but other Oct proteins have also garnered more focus over 
the years (2). 
Oct1 (Pou2f1) is a class II octamer transcription factor which contains a POU 
specific box (POUS) for recognition of the 5’ end of the octamer motif, and a POU- 
homeodomain (POUH) for recognition of the 3’ end (3–6). A close relative to Oct 4, Oct1 
is a ubiquitously expressed transcription factor involved in gene activation, repression 
and antirepression (or “poising”) (3, 7, 8). 
Modifications to Oct proteins affect stability, DNA binding capabilities, cofactor 
association, and nuclear association (3). Oct1 is modified by phosphorylation and 
ubiquitylation during mitosis (9). Under various overgrowth and metabolically stressed 




oxidative and genotoxic stress, Oct1 is dynamically phosphorylated in order to modulate 
gene expression to promote cell survival (10). 
Early findings have shown Oct1 to be involved in housekeeping gene expression, 
specifically influencing histone H2B transcription (11). Since its discovery, Oct1 has 
been found to target other functional gene groups, including various developmental 
regulators (i.e., Pax6, Hoxb1) and metabolic genes (i.e., Pcx, Hk1) (7). Oct1 also interacts 
with promoter regions of inflammatory cytokines Il2, Il3, Il5, GM-CSF, and Il4 (12, 13). 
A single gene can be modified into an active state, repressed state or poised state via Oct1 
mediated histone modifications at gene promoter sites, as seen at the T cell Il2 (3, 8). 
Oct1 has been found to be involved in a multitude of biological functions. Oct1
-/-
 
mice are embryonic lethal, with notable anemia attributed to deficiencies in 
erythropoiesis and β-globin gene expression, suggesting Oct1 plays a key role in red 
blood cell development (14). In human mesenchymal stem cells prematurely aged via 
prelamin-A accumulation, impaired Oct1 activity is described to possibly contribute to 
cellular dysfunction (15). Oct1 has been shown to work as a stress sensor that modulates 
gene expression in response stressors such as overgrowth conditions, genotoxic stress, 
gamma radiation or oxidative stress (7, 16, 17). Despite being dispensable for induced 
pluripotent stem cell development, Oct1 has been shown to be elevated in both somatic 
and cancer stem cells (2, 18). Specifically, Oct1 controls stem cell phenotype functions, 
potentiates tumor cell engraftment, and regulates hematopoietic transplant engraftment 
(18). 
Clinically, aberrant expression of Oct1 has been correlated with various forms of 








breast cancer initiating cells (18, 
19). Patient prostate cancer samples found with high levels of Oct1 expression have been 
correlated with lower patient survival rates (20). Cervical and gastric cancers both show 
similar phenomena, with the latter linking Oct1 activity to potentiated ERK 
phosphorylation associated with gastric cancer development (21, 22).  
 
Oct1 transcriptional coactivator OCA-B 
Oct proteins, including Oct1, operate under the influence of various mediators to 
modulate activity (3). OCA-B (Pou2af1, Bob.1, OBF-1) is a lymphocyte specific 
coactivator that functions as a modulator for inflammatory responses in B and T cells via 
Oct1 and Oct2 (3, 23–27). 
 OCA-B is a 256 amino acid protein that contains a stretch of seven amino acids 
near the N-terminus vital for contacting POU domain of Oct1, and the C-terminal domain 
required for transcriptional activation (23). Modifications to an acidic region of the C-
terminal domain regulate OCA-B stability and activity (28). The Oct1/OCA-B complex 
prefers adenine at the fifth position of the octamer motif (29). While Oct1 is bound to 
DNA, OCA-B makes contacts with the POUS and POUH domains to stabilize Oct1 on the 
target octamer motif in what is described as a “molecular clamp” (30).  
 In B cells, OCA-B has been found as two isoforms generated from the same 
Pou2af1 gene: p34 and p35 (31). The p35 isoform, derived from a p40 precursor isoform 
expressed upstream of the p34 locus, is anchored to the outer membrane until signaled for 
nuclear import (32). The p34 isoform is imported directly into the nuclear membrane 




counterpart (32). Overexpression of the p34 isoform causes defects at early stages of B 
cell development resulting in reduced peripheral follicular B cells and reduced pre-B cells 
in bone marrow (33). The follicular B cells produced from OCA-B overexpression show 
defects in immune responses due to irregular expression of inflammatory genes (e.g., 
HLA-DRB1, Gadd45β, TCF12) (33). 
Due to the high endogenous level in B cells, OCA-B was originally thought to be 
a B cell specific transcriptional cofactor of Oct1 and Oct2 (24). Initial findings revealed 
OCA-B strongly associating with immunoglobulin promoters in B cells, implicating the 
cofactor as a regulatory element involved in immunoglobulin production (24, 26, 27). 
Loss of OCA-B results in reduced V-D-J recombination in B cell immunoglobulin kappa 
genes (34).  
Failure to form germinal centers (GCs) is the most profound immunological 
defect in OCA-B
-/- 
mice (25). GC formation requires B cell expression of OCA-B, 
independent of functional OCA-B expression in T cells (35). OCA-B expression is 
upregulated in GC B cells (36). Along with Oct2, B cells express Il6 in an OCA-B 
dependent manner during antiviral responses, which stimulates T follicular helper cell 
differentiation (37). In a similar fashion, OCA-B facilitates B to T cell interactions during 
humoral immune response for plasma cell maturation (38). 
 With the focus on OCA-B functionality in B cells, the role of OCA-B in T cells 
has been largely overlooked. CD4
+
 T cells have no detectable amounts of endogenous 
OCA-B by northern blot, but RNA production is inducible and peaks at 4 hours with 
ionomycin/TPA treatment (39). OCA-B
-/- 
mice infected with Leishmania major exhibit 
diminished CD4
+ 
Th1 function and elevated CD4
+




higher susceptibility to infection (40). This suggests OCA-B as a possible regulator of 
Th1/Th2 population homeostasis (40). 
 Leukemia and lymphoma are two major disease states associated with altered 
expression of OCA-B (36, 41). In GC derived lymphomas, OCA-B and Oct2 were found 
to be expressed at significantly higher levels (36, 42). Clinically, Oct2 and OCA-B, along 
with Pax-5, Bcl-5 and MUM1, have been suggested as diagnostic markers for nodular 
lymphocyte predominant Hodgkin lymphoma  (43). The loss of immunoglobulin 
expression found in Hodgkin and Reed-Sternberg cells, the hallmark of transformed 
malignant cells in classical Hodgkin lymphoma, has been linked to loss of Oct2 and 
OCA-B expression (44). While no correlation of OCA-B/Oct2 over-expression is seen in 
patient leukemia samples, it has been suggested that lowered co-expression of the 
transcriptional regulators could be used to predict positive prognosis in acute myeloid 
leukemia (36, 45). Even though a mechanistic contribution has not been ascertained in 
these diseases, it is clear that misregulation of OCA-B is involved in these hematopoietic 
disease states. Further research is required to elucidate any influence OCA-B has in 




 T cell memory development 
 During an inflammatory response T cells undergo activation, clonal expansion, 
and ultimately gain effector function. A small subset of activated T cells is specialized 
and maintained as a long-term memory reservoir (46). The mechanism of CD4
+ 
memory 
pool generation is not well understood. It is known that unlike CD8
+ 
cells, T cell receptor 
(TCR) signaling plays pivotal a role in effector T-helper (Th1) CD4
+ 




development (47). More specifically, sustained interactions between CD4
+ 
T cell TCRs 
and antigens are essential for development of Th1 memory cells (48).  
Long-term survival of memory T cells is dependent on surface CD44 expression 
(49). It has been shown that engagement of surface CD44 on activated and memory Th1 
T cells provides protection from Fas-mediated apoptosis, promoting memory T cell 
development and long-term survival (49). 
 A key feature of memory T cells is a robust secondary inflammatory response. In 
naïve CD4
+ 
T cells, Oct1 represses Il2 via promoter histone deacetylation mediated by 
NuRD (8). During activation, Il2 is modified into an active state via histone 
demethylation mediated by Oct1 and histone demethylase Jmjd1a (8). After activation, 
Oct1 and Jmjd1a maintain Il2 in a poised, demethylated state allowing prompt, robust 
expression of Il2 during secondary T cell activation (8). Furthermore, Shakya et al. found 
that generation of poised gene states of inflammatory genes in T cells requires Oct1 along 
with its coactivator OCA-B (50). In addition to Il2, other genes in CD4
+ 
T cells poised in 
an Oct1/OCA-B dependent manner include: Il3, Il17a, and Ifng (50). Overall, these 
findings show that Oct1 and OCA-B are crucial factors in developing and functioning 
CD4
+  
memory T cells (50). 
 
Thesis objectives 
 The novelty of CD4
+ 
Memory T cell establishment being dependent on OCA-B 
and Oct1 implores further knowledge of OCA-B expression and functionality within 
CD4
+ 
T cells.  
OCA-B is not detectable in naïve CD4
+ 




CD3𝜀/CD28 stimulation, OCA-B is expressed at levels detectable via western blot (50). 
My first objective was to determine precisely how long naïve CD4
+ 
T cells must be 
stimulated via CD3𝜀/CD28 to begin OCA-B expression. OCA-B induction was compared 
to CD4
+ 
T cell activation marker CD69, as well as surface antigens CD44 and CD62L.  
 As described, Oct1 modulates many genes under various conditions. Based on 
this, my second objective was to investigate if Oct1 is involved in the maintenance of 
OCA-B expression in T cells after primary stimulation.  
 The final objective involved the generation of mice with floxed OCA-B alleles for 
conditional OCA-B knockout via cre drivers. Current OCA-B research involving mice 
models have been accomplished using full genotype OCA-B knockout mice and adoptive 
transfer models. Conditional OCA-B knockout mice will be an invaluable tool for 
elucidating the role OCA-B has, not only in memory CD4
+
 T cell development, but also 














OCA-B INDUCTION CHARACTERISTICS 
 
OCA-B induction in naïve CD4
+ 
T cells  
after 6-8 hours of stimulation 
 Arvind Shakya of the University of Utah’s Tantin Lab, has shown naïve CD4+ T 
cells isolated from wild-type C57/BL6 mice require at least 12 hours of CD3ε/CD28 
stimulation to begin transcription of OCA-B ((50), Figure 2.1 A). In this experiment, Dr. 
Shakya isolated naïve CD4
+ 
T cells from mice spleens using a negative enrichment 
protocol, performed in vitro stimulation via plate-bound CD3ε antibodies and CD28 
antibodies in media, and isolated protein from each sample for western blot at the 
designated times (8). I repeated the western blot experiment performed in Figure 2.1 A, 
but adjustments were made to include stimulation times of 8 hours and 10 hours. OCA-B 
expression is detectable via western blot in primary CD4
+ 
T cells following 8 hours of 
stimulation (Figure 2.1 B).  
 A shortcoming of western blot is the somewhat limited quantifiable data 
produced. Specifically, western blot looks only at global average expression of a cell 
population rather than giving a measurement of individual cellular expression. Therefore, 






Figure 2.1 OCA-B induction in naïve CD4
+
 T cells isolated from wild-type C57/BL6 
mice stimulated via CD3ε/CD28 antibodies in vitro. A) Western blot analysis of naïve 
CD4
+
 T cells stimulated via CD3ε/CD28 at times indicated showing OCA-B induction in 
naïve CD4
+
 T cells after 12 hours of stimulation, as performed by Arvind Shakya (50). B) 
A repeat of the experiment shown in A, using naïve CD4
+
 T cells isolated from 3 wild-
type C57/BL6 mice with shorter stimulation times as indicated. C) Repeat of the 
experiment shown in A, with naïve CD4
+
 T cells isolated from 3 wild-type C57/BL6 




 gated cells show OCA-B induction after 






expression. I repeated the experiment seen in Figure 2.1 B, but with a novel intracellular 




gated cells has OCA-B 
expression seen after only 6 hours of stimulation (Figure 2.1 C). OCA-B expression 
gradually increases with continued stimulation. 
 
OCA-B induction compared to  
CD69, CD62L and CD44 
 CD69 is a surface lectin receptor expressed very early in T cell activation which 
has been widely accepted as a marker for activated CD4
+ 
T cells (51). Due to its 
relatively quick induction and implication as an activation marker, it is prudent to 
compare CD69 expression patterns to OCA-B. I repeated the experimental procedures 
performed in Figure 2.1, but with shorter stimulation times, as indicated, and CD69 
staining included (Figure 2.2 A). OCA-B is found to be expressed slower and less intense 




 population is seen starting at 6 hours of 
stimulation, which increases with continued stimulation. This pattern recapitulates the 




 cells seen after 2-4 hours of stimulation 
may be a small population of “pre-activated” naïve T cells that were not removed during 
the enrichment procedures. OCA-B expression seems to precede CD44 surface 
expression and follow CD62L surface reduction.  
 Due to the novelty of intracellular OCA-B staining for flow cytometry analysis, it 
is important for this study, and future studies, to validate the staining and procedures. To 
do this, I repeated the experiment in Figure 2.2 A, but compared OCA-B expression in T 
cells isolated from wild-type mice versus OCA-B
-/- 





Figure 2.2 Comparing OCA-B induction to CD69, CD62L and CD44 surface 
markers. A) A duplication of the experiment seen in Figure 2.1, using naïve CD4
+
 T 
cells isolated from 3 wild-type C57/BL6 mice with CD3ε/CD28 stimulation times as 





cells. B) Repeating the experiment comparing naïve CD4
+ 
T cells isolated from 2 wild-
type mice and 2 OCA-B
-/-
 mice for validation of antibody staining of intracellular OCA-


















mice show no induction of OCA-B regardless of any amount of 
stimulation, whereas CD69 and CD62L show expected modulation after stimulation. In 
addition to CD69 and CD62L modulation, wild-type mice have induction of OCA-B 
expression seen after 8 hours of stimulation, as seen before. Interestingly, surface CD44 
is absent in OCA-B
-/-
 regardless of any amount of stimulation. 
 
Does OCA-B induction require constant stimulation? 
 It has been shown that development of memory CD4
+ 
T cells depends on long, 
sustained interactions between TCRs and TCR specific antigens (48). With these findings 
in mind, we hypothesized that sustained stimulation of naïve CD4
+
 T cells is required for 
OCA-B expression. To test this hypothesis, naïve CD4
+
 T cells were isolated from 3 
wild-type mice and plated for various times with CD3ε/CD28 antibodies, washed, and 
replated without any stimulation. Primary CD4
+ 
T cells were stimulated for 6, 8, 10 and 
12 hours with overall plate times capped at 12 hours. One aliquot was plated for 12 hours 





cells (Figure 2.3). OCA-B is found to have a steady increase of expression after 6 hours 
of stimulation based on the length of stimulation given, in a pattern similar to previous 
figures.  
 
Oct1 maintains OCA-B expression in activated T cells 
 Arvind Shakya showed that OCA-B expression is maintained in T cells rested 8 
days poststimulation. ((50), Figure 2.1 A). To query if Oct1 is involved in maintaining 
OCA-B expression, naïve CD4
+ 










Figure 2.3 Evaluating stimulation requirement for OCA-B induction. Naïve CD4
+
 T 
cells isolated from 3 wild-type C57/BL6 mice were plated with or without CD3ε/CD28 











cre mice, stimulated for 2 days, then rested for 8 days with Il2 in media. OCA-B 






cells (Figure 2.4). 
Between the two groups of cells, naïve cells and cells stimulated followed the same 
induction kinetics for OCA-B, as wells as CD69, CD62L and CD44. After the stimulated 
cells were rested for 8 days with Il2 in media, OCA-B protein levels were reduced in 
Oct1 deficient T cells while wild-type T cells maintained OCA-B expression.  
 
Discussion 
OCA-B induction after 6-8 hours of stimulation 
 As shown in my data, and data from previous research efforts, naïve CD4
+ 
T cells 
do not have endogenous expression of OCA-B (Figure 2.1, Figure 2.2, Figure 2.3, Figure 
2.4 (18, 39)). The data presented demonstrate that in vitro CD3ε/CD28 stimulation with 
antibodies induces detectable OCA-B expression at 6 hours via flow cytometry, which is 
detectable after 8 hours via western blot. Additionally, OCA-B expression progressively 
increases with continued stimulation after 6 hours. Compared to activation marker CD69, 
OCA-B induction is much slower and less robust. After 2 days of stimulation, OCA-B 
expression has increased beyond levels seen after 12 hours of stimulation, whereas CD69 
expression seemingly peaks after 6-8 hours of stimulation and remains at approximately 
the same level after 2 days of stimulation (Figures 2.2 B, 2.4). This provides some 
evidence that OCA-B induction is a long, gradual process which may require extended 
stimulation. 
Sauter et al. detects OCA-B mRNA in primary T cells after 1 hour of 







Figure 2.4 Oct1 is involved in OCA-B expression maintenance in activated T cells. 
Naïve CD4
+
 T cells were isolated from a wild-type C57/BL6 mouse and an Oct1
fl/Δ 
CD4-
cre mouse. Flow cytometry was performed on sample aliquots taken before stimulation; 
after 2 days of CD3ε/CD28 stimulation; and after 8 days of rest with Il2 in media, 










Considering OCA-B protein is detected at 6 hours, it seems there is a posttranscription to 
translation lag of approximately 5 hours. However, ionomycin/TPA treatment bypasses 
multiple signal transduction steps seen in vivo, activating T cells by means of direct PKC 
interactions. While it is still an in vitro means to activate T cells, CD3ε/CD28 stimulation 
using antibodies more closely resembles T cell activation by APCs in vivo and includes 
more signal transduction steps. With this in mind, and the fact that Sauter et al. did not 
isolate purely for naïve CD4
+ 




vs WT naïve T cell stimulation induction profiles 
 As expected, OCA-B
-/- 
T cells have no OCA-B expression found even after 48 
hours of stimulation (Figure 2.2 B). Conversely, OCA-B is significantly stained in wild-
type T cells stimulated for 48 hours. It should be noted that there is a slight discrepancy 
in early OCA-B induction in wild-type CD4
+ 
T cells in Figure 2.2B compared to previous 
flow plots. The OCA-B detected after 4 hours of stimulation is most likely attributed to 




T cells, as seen in the “naïve” column, which 





T cells showed no surface expression of CD44 









mice, have no noticeable decrease in CD44 RNA expression (50). 
Therefore, OCA-B dependent transcription of CD44 can be ruled out. CD44 has many 
isoforms and is posttranslationally modified to direct its function and localization (52). 
With this in mind, the argument could be made that a separate transacting protein is 




appropriately for surface expression. Additionally, since Oct1 deficient T cells have 
appropriate surface expression of CD44 after 48 hours of stimulation, as seen in Figure 
2.4, there is a distinct possibility that CD44 surface localization is dependent on OCA-B 
with a different transcriptional modifier aside from Oct1. Considering other roles in 
inflammation, Oct2 could possibly be the alternative transcriptional modulator involved 
in this mechanism.  
The influence of OCA-B on CD44 surface expression is novel and, as such, leads 
to new lines of inquiry. Primarily, it would be interesting to probe if OCA-B deficient 
naïve T cells have the same level intracellular CD44 compared to wild-type naïve T cells. 
If OCA-B deficient
 
naïve T cells exhibit lowered intracellular CD44, then OCA-B may 
indirectly influence CD44 translation rather than CD44 posttranslational modifications. 
Overall, this finding provides further insight into the role OCA-B plays in 
memory CD4
+ 
T cell development. Baaten et al. found that engagement of the surface 
CD44 receptor counteracts Fas mediated apoptosis via P13k/Akt activation, which 
promotes the long-term survival of memory Th1 T cells (49). If OCA-B truly does effect 
CD44 surface expression, then it can be deduced that OCA-B indirectly influences the 
survival of memory T cells.  
 
Induced OCA-B stimulation requirements 
By studying TCR/antigen kinetics, Kim et al. found a correlation between TCRs 
and respective antigens with increased binding length in memory T cells (48). The group 
concluded that sustained TCR and antigen interactions promote development of memory 
CD4
+ 






require constant stimulation to induce OCA-B expression. I tested this hypothesis by 
comparing OCA-B expression in naïve CD4
+ 
T cells stimulated for short periods to cells 
stimulated for longer windows. Unfortunately, the data gathered have not entirely 
answered this question and it is still unclear if OCA-B induction requires sustained T cell 
stimulation. However, given that shorter windowed T cell stimulation closely duplicates 
the induction patterns of strictly stimulated T cells, the hypothesis cannot be excluded 
(Figure 2.1 C, Figure 2.2, Figure 2.3). These matching results from the two experimental 
designs and the noted increase in OCA-B expression between 8 and 48 hours do suggest 
that constant stimulation may play a role in OCA-B induction. 
Kim et al. developed multiple TCR clones with well documented dissociated 
constants and tetramer binding half-lives. It would be interesting to see if TCR clones 
identified to generate memory T cell phenotypes have corresponding OCA-B induction. 
Comparing OCA-B expression in cloned TCRs with longer antigen binding times 
compared to TCRs with shorter binding times would provide interesting insight into 
stimulation requirements for OCA-B induction.  
 
OCA-B expression is insulated by Oct1 
As previously described, Oct1 modulates genes into active, suppressed or poised 
expression states. While research has looked into the cooperation of Oct1 and OCA-B as 
transacting gene regulators, modification of Pou2af1 expression by Oct1 has not been 
described. Between Oct1 deficient and wild-type naïve CD4
+
 T cells, no difference is 
noted in OCA-B expression after 2 days of stimulation (Figure 2.4). After stimulated 












 cells, exhibit 
diminished expression of OCA-B. Wild-type T cells maintain OCA-B expression after 
rest equal to cells stimulated for 2 days.  
In CD4
+ 
T cells selected for memory differentiation, together Oct1 and OCA-B 
modulate expression and inflammatory gene promoters to prime stimulated T cells for a 
robust secondary response (50). Here, we see that loss of Oct1 in T cells impairs the 
ability to maintain OCA-B expression after stimulation. However, 8 days of rest is a 
relatively short time compared to the longevity of naturally developed memory T cells. 
As done by Shakya et al., it would be interesting to see how drastically Oct1deficiency 
diminishes OCA-B expression maintenance in T cells rested for weeks or months post-
stimulation. If Oct1 is determined essential for maintenance of long-term OCA-B 
expression, and given the amount of OCA-B lost 8 days after stimulation, I hypothesize 
that OCA-B should be absent in T cells rested for 4 to 6 weeks poststimulation. 
Alternatively, if OCA-B expression is not entirely lost after a long period of rest, it would 
be interesting to see if OCA-B expression is as robust in Oct1 deficient T cells compared 
to wild-type T cells in response to secondary stimulation.
 
 
OCA-B: memory marker and memory precursor? 
Surface expression of CD44 has been previously determined as both a memory T 
cell marker as well as a receptor required for long-term survival of memory T cells (49). 
After 12 hours of stimulation, OCA-B is expressed initially in CD44
LO 
T cells (Figure 2.1 
C, Figure 2.2). After 48 hours of stimulation, T cells induce CD44 surface expression 




known that Oct1 and OCA-B are essential factors for memory T cell development (50). 
Providing Oct1 assists in long-term OCA-B expression, and OCA-B feasibly controls 
CD44 surface expression, it could be inferred that OCA-B expression is indicative of a T 
cell selected for memory development (Figure 2.4, Figure 2.2). It could be further 
extrapolated that CD4
+
 “memory precursors” are CD44LO, CD69HI; and OCA-BHI T cells 
that modulate into CD4
+









 As shown and discussed, naïve CD4
+ 
T cells require 6 hours of CD3ε/CD28 
stimulation to begin OCA-B expression. OCA-B induction is slower compared to 
activation marker CD69, and expression increases gradually with continued stimulation. 
It has not been fully ascertained if constant stimulation is required for OCA-B expression. 
However, considering the slow increase of OCA-B expression over time, the hypothesis 
cannot be ruled out. Maintenance of OCA-B expression is influenced by Oct1, but it is 
not entirely evident if maintenance is entirely lost in the absence of Oct1.  
 Interestingly, it seems that OCA-B may influence the surface localization of 












T cell isolation 
 Naïve CD44
+ 
T cells were isolated from C57/BL6 mice spleens as described (8). 






Cell culture and in vitro stimulation 
 
 Isolated T cells were cultured and stimulated with plate bound anti-CD3ε and 
anti-CD28 antibodies as described (8). Culturing times are as described in the results. 
 
Western blot 
 Western blot was done using standard procedures. OCA-B blotting was done with 
rabbit anti-Bob.1 (OCA-B)(c-20) antibody (Bethyl) at a 1:500 dilution in TBST. β-actin 
blotting was done with mouse anti-β-actin (Abcam) at a 1:1000 dilution in TBST. 
 
Flow cytometry 
Flow cytometry surface staining was done following standard procedures using 
the following stains: Af700-CD4 (1:500); pcpCy5.5-CD8 (1:500); PECy7-CD44 
(1:2000); APC-CD62L (1:2000); FITC-CD69 (1:1000). Data were collect using a 
FacsCantoII and analyzed using FlowJo software (Becton-Dickenson). 




 cells were washed in 
200 µl PBS plus 3% fetal bovine serum, and fixed/permeabilized in 100 µL 
Cytofix/Cytoperm (Becton-Dickenson). Cells were vortexed and incubated for 20 
minutes on ice. Subsequently 100 µl of Perm/Wash buffer (Becton-Dickenson) was 
added, and cells were collected by centrifugation. Cells were resuspended in 100 µL 
Perm/Wash buffer plus 15 µL anti-OCA-B-PE (Santa Cruz sc-23932), briefly vortexed, 
and incubated for 40 minutes at 4°C. Following addition of 100 µL of Perm/Wash buffer 


















 Recombinant mice derived from embryonic stem cells with promotor driven 
knockout of OCA-B (Pou2af1
tm1a(KOMP)Wtsi
) were purchased from the UC Davis KOMP 
repository. The OCA-B locus, as generated by UC Davis, includes: an En2 splice 
acceptor (En2 SA), an internal ribsome entry site (IRES), a beta-galactosidase reporter 
gene (LacZ), human beta-actin promoter (hBactP), and a neomycin cassette (neo) (Figure 
3.1 A (top)). All of these accessory genes are flanked by two FRT recombination sites. 
As such, the mice were crossed with mice expressing FLP recombinase resulting in a 
functional OCA-B locus with loxP sites flanking around exons 1, 2 and 3 (Figure 3.1 A 
(middle)). The resulting “post-FLP” mice will work as the core mice for any future 
conditional knockout experiments. A truncated knockout of OCA-B results when crossed 
with a mouse expressing either tissue specific or ubiquitous cre recombinase (Figure 3.1 
A (bottom)).  Full body knockout (“Null”) alleles were generated by crossing post-FLP 





Figure 3.1 Conditional knockout mice genome map and PCR genotyping strategies. 
A) A representation of the promotor driven conditional knockout OCA-B locus of mice 
generated from the UC Davis KOMP Repository (top), crossed onto a FLP recombinase 
mouse (middle), and further crossed to a cre recombinase for a null or tissue specific 
knockout allele (bottom). B) Diagrams of amplicons resulting from respective PCR 


















 UC Davis KOMP Repository designed primers with theoretical amplicons as 
represented in Figure 3.1 B. Resulting PCR products of mice currently available are as 
represented in Figure 3.1 C. It is important to note that the Null primer set gives an  
unidentified, nonspecific band at approximately 1000 base pairs. According to UC Davis 
representatives, there is nothing at this locus which could result in such a band. As long 
as care is taken to run the gel accordingly, this nonspecific band is easily distinguishable 
from the null allele.  





Δ/Δ animals is underway, but 
considering the viability of OCA-B
-/-
 mice as seen in other experiments, any homozygous 
allele is expected to have a viable phenotype. Provided that it demonstrates OCA-B 
sufficiency (e.g., protein expression, germinal center formation), the floxed OCA-B allele 
isolated in this project will be an invaluable tool for further researching the role OCA-B 
has, not only in memory T cell differentiation, but also in OCA-B related hematopoietic 
disease states.  
 
Methods 
OCA-B specific PCR recipe and parameters 
 DNA was isolated from mice tail tips using standard HotSHOT tail DNA 
preparation procedures. Genotype protocols and primer designs were as provided from 
UC Davis Komp repository.  
 A 1.5 µL sample of DNA was combined with the following: 9.08 µL autoclaved 




(Life Technologies); 0.4 µL 10 mM dNTPs; 1.0 µL forward primer; 1.0 µL reverse 
primer; 0.20 µL Phire HotStart Taq Pol II (Life Technologies).  
The PCR cycling parameters for each genotype are as follows: 94°C for 5 
minutes; 94°C for 15 seconds to 65°C for 30 seconds to 72°C for 40 seconds repeated 10 
times with a 1°C decrease per cycle; 94°C for 15 seconds to 55°C for 30 seconds to72°C 
for 40 seconds repeated 30 times; 72°C for 5 minutes; 4°C until removed for analysis.  
 
OCA-B primer design 
Primers for wild-type OCA-B and post-FLP recombination are as follows: CSD-
OCAB-F (aka. CSD-Pou2af1-F) 5’- TACAGAGAGACTAGACACGGTCTGC-3’ and 
CSD-OCAB-ttR (aka. CSD-Pou2af1-ttR) 5’-AGAAGGCCTCGTTACACTCCTATGC-
3’.  
Primers for floxed OCA-B are as follows: CSD-Lox-F 5’-
GAGATGGCGCAACGCAATTAATG-3’ and CSD-OCAB-R (aka. CSD-Pou2af1-R) 5’- 
GATGAGGACTCTGGGTTCAGAGAGG-3’.  
Primers for null OCA-B are as follows: CSD-OCAB-F (aka. CSD-Pou2af1-F), 5’-
TACAGAGAGACTAGACACGGTCTGC-3’ and CSD-OCAB-R (aka. CSD-Pou2af1-R) 
5’- GATGAGGACTCTGGGTTCAGAGAGG-3’. 
 
LacZ PCR recipe and parameters 
 A 1.5 µL sample of DNA was combined with the following: 16.9 µL autoclaved 
dH2O; 5.0 µL 5x Phire HotStart reaction buffer (Life Technologies); 0.4 of 10 mM 




(Life Technologies).  
The PCR cycling parameters for LacZ PCR are as follows: 94°C for 5 minutes; 
94°C for 20 seconds to 59°C for 20 seconds to 72°C for 40 seconds repeated 29 times; 
72°C for 10 minutes; 4°C until removed for analysis.  
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